Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Clobazam is a benzodiazepine derivative widely utilized in the global pharmaceutical market for its potent anticonvulsant properties. Chemically, it is distinguished by a unique 1,5-benzodiazepine structure, which sets it apart from other drugs in its class that typically feature a 1,4-benzodiazepine backbone. This structural difference contributes to its favorable safety profile and reduced risk of sedation compared to traditional benzodiazepines. The molecular formula of Clobazam is C16H13ClN2O, reflecting its composition of sixteen carbon atoms, thirteen hydrogen atoms, one chlorine atom, two nitrogen atoms, and one oxygen atom. Its official CAS registry number is 290-87-3, a unique identifier essential for regulatory compliance and chemical inventory management worldwide.
The primary clinical application of Clobazam is the adjunctive treatment of epilepsy, specifically for managing partial seizures with or without secondary generalization. It has gained significant approval for use in Lennox-Gastaut syndrome, a severe form of childhood-onset epilepsy characterized by multiple seizure types and cognitive impairment. By enhancing the activity of gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system, Clobazam effectively reduces neuronal excitability and prevents the spread of seizure activity. Unlike many other antiepileptic drugs, Clobazam exhibits a relatively low potential for drug interactions, making it a preferred choice for pediatric patients and those on complex medication regimens. Furthermore, its active metabolite, N-desmethylclobazam, possesses comparable pharmacological activity and a longer half-life, ensuring sustained therapeutic effects. While generally well-tolerated, common side effects may include drowsiness, fatigue, and increased appetite. Regulatory bodies such as the US FDA and the European Medicines Agency have approved various formulations, including tablets and oral suspension, to accommodate diverse patient needs. As research continues, Clobazam remains a cornerstone therapy in neurology, offering a critical balance between efficacy and tolerability for individuals suffering from refractory seizure disorders.